Journal article
Indium‐111‐labeled anti‐egfr‐425 scintigraphy in the detection of malignant gliomas
Cancer, v 73(S3), pp 884-889
01 Feb 1994
PMID: 8306274
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background. The monoclonal antibody anti‐epidermal growth factor receptor (EGFr)antibody‐425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue.1–3 A prospective study was conducted (1986–1988) to evaluate the use of Indium‐111 (111In)‐labeled anti‐EGFr‐425 in the localization of gliomas before radioimmunotherapy with Iodine‐125 (125I)‐labeled anti‐EGFr‐425.
Methods. Twenty‐eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111In‐labeled anti‐EGFr‐425. Planar and single‐photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111In‐labeled Co 17‐1A (a, *I antibody to colorectal cancer) and in one case with unlabeled 111In chloride.
Results. The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111In‐labeled anti‐EGF‐425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90.
Conclusion. Immunoscintigraphy with 111‐In labeled anti‐EGFr‐425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125I‐labeled anti‐EGFr‐425. Cancer 1994; 73:884–9.
Metrics
Details
- Title
- Indium‐111‐labeled anti‐egfr‐425 scintigraphy in the detection of malignant gliomas
- Creators
- Simin Dadparvar - Hahnemann University HospitalLalitha Krishna - Hahnemann University HospitalCurtis Miyamoto - Hahnemann University HospitalLuther W. Brady - Hahnemann University HospitalSteven J. Brown - Hahnemann University HospitalHans Bender - Hahnemann University HospitalWalter J. Slizofski - Hahnemann University HospitalJeffrey Eshleman - Hahnemann University HospitalAnita Chevres - Hahnemann University HospitalDavid V. Woo - Hahnemann University Hospital
- Publication Details
- Cancer, v 73(S3), pp 884-889
- Publisher
- Wiley Subscription Services, Inc., A Wiley Company
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:A1994MV41800019
- Scopus ID
- 2-s2.0-0028032152
- Other Identifier
- 991019183916204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology